Your trusted source for GLP-1 research, news, and patient insights.
26 posts in this category
PCOS has been renamed PMOS. See what the new name means, why it changed, and what the research shows about GLP-1s for this common condition.
MariTide is an experimental once-monthly weight-loss shot in Phase 3. See how it works, what trials showed, and how it compares to weekly shots.
Brand GLP-1 cash prices are falling fast. See what Ozempic, Wegovy, and Zepbound cost now, why, and whether your own bill will drop.
The FDA moved 12 peptides off its restricted list and reviews 7 in July 2026. See what it could mean for compounding, your GLP-1, and peptide safety.
AstraZeneca's elecoglipron, an experimental once-daily GLP-1 pill, is heading to Phase 3. See what the early results show and what is still unproven.
Foundayo has an FDA boxed warning for thyroid C-cell tumors. See what it means, what the research shows, and what it means for you.
Medicaid coverage for GLP-1s expands through December 2031 under the BALANCE Model. Eligibility, pricing, and what to ask your state Medicaid agency.
California AB 1990 cleared Appropriations 13-0 and heads to the Assembly floor. Latest amendments, opposition, and what it means for GLP-1 patients.
Lilly wants retatrutide classified as a biologic, but the FDA is not agreeing, now there is a lawsuit. What the lawsuit and OFA brief actually say.
Canada is approving generic Ozempic, India already has. Here is what it means for US prices, when patents expire, and what you can actually do today.
What are peptides and how do they differ from GLP-1 medications? A plain-language guide to BPC-157, CJC-1295, ipamorelin, and more.
India’s GLP-1 patent expiry may lower prices there first. Learn what it could mean for US access and affordability.
Major GLP-1 and obesity drug trials are finishing in 2027. Here’s what they’re studying and what it could mean for access and affordability.
Learn how TrumpRx coupons work, who qualifies, where they’re accepted, and what to watch for before starting GLP-1 meds long term.
Early trials of gene-silencing drugs plus GLP-1s show promising fat loss, but big questions remain. Here is what the science suggests so far.
Retatrutide shows major Phase 3 weight-loss results but remains investigational. Learn what’s real in 2026 and why social ads can be misleading.
GLP-1 drugs aren’t FDA-approved for PCOS, but research and off-label use are growing. Here’s what science and real-world data show in 2026.
How telehealth access to GLP-1s is changing in 2026, including intake, follow-up, transparency, and what members should expect.
Scientists are testing GLP-1 therapy for overweight pets. Learn how these trials work and what they could mean for cats and dogs.
Learn what orforglipron is, how this daily oral GLP-1 works, where the research stands now, and what to watch for as it moves toward FDA review.
New GLP-1 Alzheimer’s trials found semaglutide did not slow memory loss. Learn what this means for brain health, GLP-1 users, and future research.
Confused about how Medicare may cover GLP-1 weight loss drugs after the TrumpRx deal Learn who may qualify, expected costs, and key dates until 2027.
A clear look at the next wave of GLP-1 drugs in 2026 — launches, filings, access changes and what patients and payers should know.
Trump’s plan could cut GLP-1 drug prices — like Ozempic® and Wegovy® — to $150/month. Here’s what’s real, what’s pending, and who it helps.
Learn what’s changing in 2026 insurance plans for GLP-1 drugs and how to compare costs, coverage, and plan options to stay protected.
New oral GLP-1 pills may soon replace injections—but are they safe and effective? Learn what’s coming and how to avoid fake patches.
